Steve Rowland
Overview
Explore the profile of Steve Rowland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
116
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iwamoto S, Cavanaugh K, Malone M, Lottes A, Thatcher R, Kumar K, et al.
Cardiovasc Revasc Med
. 2023 Mar;
52:67-74.
PMID: 36870799
As medical device development becomes increasingly global, the opportunities and potential advantages offered by international clinical trial and regulatory approval strategies are also growing. In particular, medical device clinical trials...
2.
Larsen K, Cheng C, Tempel D, Parker S, Yazdani S, den Dekker W, et al.
Eur Heart J
. 2011 Jul;
33(1):120-8.
PMID: 21733913
Aims: The Genous™ Bio-engineered R™ stent (GS) aims to promote vascular healing by capture of circulatory endothelial progenitor cells (EPCs) to the surface of the stent struts, resulting in accelerated...
3.
Burch J, Farand J, Colucci J, Sturino C, Ducharme Y, Friesen R, et al.
Bioorg Med Chem Lett
. 2011 Jan;
21(3):1041-6.
PMID: 21215624
Two new series of EP(4) antagonists based on naphthalene/quinoline scaffolds have been identified as part of our on-going efforts to develop treatments for inflammatory pain. One series contains an acidic...
4.
Boyd M, Berthelette C, Chiasson J, Clark P, Colucci J, Denis D, et al.
Bioorg Med Chem Lett
. 2010 Dec;
21(1):484-7.
PMID: 21126875
A novel series of EP(4) ligands, based on a benzyl indoline scaffold, has been discovered. It was found that agonism and antagonism in this series can be easily modulated by...
5.
Colucci J, Boyd M, Berthelette C, Chiasson J, Wang Z, Ducharme Y, et al.
Bioorg Med Chem Lett
. 2010 May;
20(12):3760-3.
PMID: 20471829
The discovery of a highly potent and selective EP(4) antagonist MF-766 is discussed. This N-benzyl indole derivative exhibits good pharmacokinetic profile and unprecedented in vivo potency in the rat AIA...
6.
Granada J, Inami S, Aboodi M, Tellez A, Milewski K, Wallace-Bradley D, et al.
Circ Cardiovasc Interv
. 2010 May;
3(3):257-66.
PMID: 20442358
Background: We aimed to demonstrate that, by separating endothelial progenitor cell capture from sirolimus delivery through the application of drug to the abluminal surface of the stent, the degree of...
7.
Blouin M, Han Y, Burch J, Farand J, Mellon C, Gaudreault M, et al.
J Med Chem
. 2010 Feb;
53(5):2227-38.
PMID: 20163116
The discovery of highly potent and selective second generation EP(4) antagonist MK-2894 (34d) is discussed. This compound exhibits favorable pharmacokinetic profile in a number of preclinical species and potent anti-inflammatory...
8.
Burch J, Belley M, Fortin R, Deschenes D, Girard M, Colucci J, et al.
Bioorg Med Chem Lett
. 2008 Feb;
18(6):2048-54.
PMID: 18291643
A new series of EP(4) antagonists based on a quinoline acylsulfonamide scaffold have been identified as part of our on-going efforts to develop treatments for chronic inflammation. These compounds show...
9.
Pulichino A, Rowland S, Wu T, Clark P, Xu D, Mathieu M, et al.
J Pharmacol Exp Ther
. 2006 Sep;
319(3):1043-50.
PMID: 16973887
The inhibition of prostaglandin (PG) synthesis is at the center of current anti-inflammatory therapies. Because cyclooxygenase-2 (COX-2) inhibitors and nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the formation of multiple PGs, there...